Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. (NASDAQ: ADTX) regularly issues news and regulatory updates that describe its activities as a social innovation platform accelerating promising health innovations. Company news often highlights developments across its programs in immune health, precision diagnostics, autoimmunity, cancer and early disease detection, infectious diseases, and women’s health, as well as platform-level initiatives such as the bitXbio™ strategy.
Recent announcements have focused on the evolution of Aditxt’s bitXbio™ framework, which the company describes as a transformational approach intended to connect public markets, blockchain and Web3 concepts, digital asset treasuries, and life sciences operating companies. News items have discussed proxy proposals related to an Employee Stock Purchase Plan, equity incentive plan changes, and a non-binding advisory vote on a proposed name change from “Aditxt, Inc.” to “bitXbio, Inc.”
Updates about Aditxt’s subsidiaries and ventures are another recurring theme. For example, the company has reported on Adimune, a wholly owned subsidiary developing a DNA-based therapeutic platform to reprogram the immune system, including information on its patent portfolio and plans related to first-in-human trials for conditions such as type 1 diabetes and stiff person syndrome. News has also covered Pearsanta, Aditxt’s precision diagnostics subsidiary, including the start of enrollment in a clinical study of the Mitomic® Endometriosis Test (MET™) and Pearsanta’s work with Mitomic® and Adductomics testing platforms.
Capital markets and corporate governance developments appear frequently in Aditxt’s news flow. The company has issued press releases about a 1-for-113 reverse stock split intended to address Nasdaq’s minimum bid price requirement, as well as proxy statements and special meetings to approve issuances of common stock underlying preferred stock and warrants, an Employee Stock Purchase Plan, and changes to its equity incentive plan.
Investors and observers who follow ADTX news can use this stream of press releases and related filings to track how Aditxt describes the progress of its platform strategy, its health-focused programs, its relationships with companies such as Evofem Biosciences, and its ongoing corporate and capital structure actions. Returning to this page provides a way to review the company’s official communications over time.
Aditxt, Inc. (Nasdaq: ADTX) has successfully closed a public offering, selling 3,333,333 shares of common stock and warrants at a combined price of
Aditxt, Inc. (Nasdaq: ADTX) announced a public offering of 3,333,333 shares of common stock and associated warrants at $6.00 per unit, aiming to raise approximately $20 million. The warrants, with an exercise price of $6.00, are exercisable immediately and expire in five years. Proceeds will fund general corporate expenses, including R&D and potential acquisitions, although no current commitments are in place. Closing of the offering is expected around September 20, 2022, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent.
Aditxt, Inc. (Nasdaq: ADTX) announced a 1-for-50 reverse stock split effective September 13, 2022. The split aims to comply with Nasdaq's $1.00 per share minimum bid price requirement. Post-split, approximately 1,156,674 shares will be outstanding with the CUSIP number 007025505. The reverse split was approved by stockholders during a special meeting on September 7, 2022. Trading on a post-split basis will begin on September 14, 2022. Aditxt focuses on immune system monitoring and modulation technologies.
Aditxt, Inc. (NASDAQ: ADTX) announces positive results from a toxicology study for its immunotherapeutic drug ADI™-100, aimed at treating autoimmune diseases and organ transplantation rejection. The study demonstrated a robust safety profile with no premature deaths or adverse clinical signs. These findings will support an upcoming Investigational New Drug (IND) application. Aditxt's commitment to advancing innovative solutions in the biotech sector is emphasized by the encouraging results, positioning ADI™-100 for potential human trials.
On June 14, 2022, Premier Medical Laboratory Services (PMLS) announced the addition of AditxtScore™ to its testing services, aimed at providing insights into patients' immunity profiles against SARS-CoV-2. The test assesses multiple antibodies and their effectiveness, enabling individuals to make informed decisions on vaccinations and risk mitigation. PMLS, a CAP accredited lab with extensive COVID-19 testing experience, emphasizes the importance of monitoring immunity trends as new variants emerge. AditxtScore™ can also help employers optimize testing protocols and reduce workplace disruptions.
Aditxt, Inc. (NASDAQ: ADTX) has announced a multiyear partnership with GRS, an affiliate of Guthy-Renker, to enhance awareness of its AditxtScore™ Immune Monitoring Platform. This collaboration aims to produce and broadcast TV commercials to boost visibility among consumers and healthcare providers. The AditxtScore™ technology, which provides insights into immune status related to COVID-19, is now fully operational in Richmond, VA. Aditxt's partnership with GRS leverages extensive marketing experience to facilitate a national rollout of AditxtScore™.
Aditxt, Inc. (NASDAQ: ADTX) has entered into a revenue-sharing agreement with Cellvera, enhancing its revenue strategy starting in 2022. The agreement aims to secure a $14.5 million loan while allowing Aditxt to earn up to 10% of Cellvera's net sales, reaching a maximum of $30 million. This deal is a step toward Aditxt's potential acquisition of Cellvera, which specializes in developing antiviral therapies. Due diligence for the acquisition is ongoing, with no guarantee of completion.
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company, announced that CEO & Co-Founder Amro Albanna will present at the 2022 Virtual Growth Conference, hosted by Maxim Group LLC and M-Vest from March 28th - 30th between 9:00 a.m. - 5:00 p.m. EDT. This conference will cover various sectors, including biotech and healthcare, featuring presentations, discussions, and Q&As with executives. Aditxt focuses on mapping and reprogramming the immune system, aiming to address organ rejection and autoimmune diseases.
Aditxt has officially submitted two Emergency Use Authorization (EUA) applications for its AditxtScore™ COVID-19 test to the FDA, meeting the January 14 deadline. This comprehensive blood test assesses the immune response to COVID-19 and its variants, including Omicron. Notably, the test evaluates levels of neutralizing antibodies to the virus and those targeting its spike and nucleocapsid proteins. AditxtScore™ continues to be available during the FDA review process, aiming to provide critical insights into COVID-19 immunity.
Aditxt, Inc. (NASDAQ: ADTX) is participating in Edison Group’s Global Healthcare Open House Event from January 25 to 27, 2022. The virtual event, hosted in collaboration with the London Stock Exchange and Taylor Wessing, will cover topics including pharmaceuticals, AI, and healthcare technology. Presentations will be available for streaming on Edison’s website. Interested participants can register for free. Additionally, Aditxt focuses on immune system health and offers technology for immune monitoring and reprogramming, including the AditxtScore™ for COVID-19.
FAQ
What is the current stock price of Aditxt (ADTX)?
What is the market cap of Aditxt (ADTX)?
